May 21, 2026

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

May 19, 2026

Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 07, 2026

Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 23, 2026

Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time

Mar 17, 2026

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

Mar 06, 2026

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

Mar 02, 2026

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®

Feb 26, 2026

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 24, 2026

Lantheus to Present at March 2026 Investor Conferences